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GENE THERAPY
T-cell receptor gene transfer exclusively to human CD8 cells enhances tumor
cell killing
Qi Zhou,1 Irene C. Schneider,1 Inan Edes,2 Annemarie Honegger,3 Patricia Bach,1 Kurt Scho¨nfeld,4 Axel Schambach,5
Winfried S. Wels,4 Sabrina Kneissl,1 Wolfgang Uckert,2 and Christian J. Buchholz1
1Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany; 2Max-Delbru¨ck Center for Molecular Medicine and Humboldt-University
Berlin, Institute of Biology, Berlin, Germany; 3Department of Biochemistry, University of Zu¨rich, Zu¨rich, Switzerland; 4Chemotherapeutisches Forschungsinstitut
Georg-Speyer-Haus, Frankfurt am Main, Germany; and 5Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany
Transfer of tumor-specific T-cell receptor
(TCR) genes into patient T cells is a
promising strategy in cancer immuno-
therapy. We describe here a novel vector
(CD8-LV) derived from lentivirus, which
delivers genes exclusively and specifi-
cally to CD8 cells. CD8-LV mediated
stable in vitro and in vivo reporter gene
transfer as well as efficient transfer of
genes encoding TCRs recognizing the
melanoma antigen tyrosinase. Strikingly,
T cells genetically modified with CD8-LV
killed melanoma cells reproducibly more
efficiently than CD8 cells transduced
with a conventional lentiviral vector. Nei-
ther TCR expression levels, nor the rate
of activation-induced death of trans-
duced cells differed between both vector
types. Instead, CD8-LV transduced cells
showed increased granzyme B and perfo-
rin levels as well as an up-regulation of
CD8 surface expression in a small sub-
population of cells. Thus, a possible
mechanism for CD8-LV enhanced tumor
cell killing may be based on activation of
the effector functions of CD8 T cells by
the vector particle displaying OKT8-
derived CD8-scFv and an increase of the
surface density of CD8, which functions
as coreceptor for tumor-cell recognition.
CD8-LV represents a powerful novel vec-
tor for TCR gene therapy and other appli-
cations in immunotherapy and basic re-
search requiring CD8 cell-specific gene
delivery. (Blood. 2012;120(22):4334-4342)
Introduction
In the human body, a vast diversity of immune cells constantly
patrols the blood stream and tissues to protect from invaders. Each
type of these immune cells fulfills different functions. Genetic
modification of these cells is a key technology to elucidate their
physiologic functions and to develop novel therapeutic strategies.
Among the different types of gene vector systems available,
-retroviral and lentiviral vectors (LVs) have become state-of-the-
art technology for lymphocyte gene transfer.1-3 Failure to distin-
guish between subtypes of cells and thereby transferring genes to
both target and nontarget cells is a limitation of vector systems
currently in use. Selective and specific delivery of transgenes into
particular types of lymphocytes is highly desirable for immuno-
therapy and gene therapy. Although few attempts have been
undertaken to retarget LVs to CD3 T cells,4 the transduction of
subpopulations or even the transfer of therapeutic genes by such
targeting vectors has not been described. In addition, no targeting
vector specific for CD8 T cells has been described. CD8 T cells
are among the most important immune cell types and also a
primary target for immunotherapy because of their capacity to
directly engage and kill pathogen infected cells or tumor cells.5
Adoptive transfer of tumor-specific T cells is a promising strategy
of directed tumor cell killing, which is currently under investiga-
tion in clinical trials worldwide.6-9 Tumor specificity is provided by
an antigen receptor, which can be natural (T-cell receptor; TCR) or
engineered (chimeric antigen receptor, CAR). Whereas TCR
gene-modified T cells recognize peptide-major histocompatibility
complex (pMHC), CAR recognize antigen in an MHC-independent
fashion. In each case, the receptor encoding sequence is transferred
into patient T cells, which are then amplified to generate a large
number of tumor-specific T cells for cancer treatment. With current
technology, TCR genes are transferred into all types of T cells as
the vectors do not distinguish between T-cell subtypes, such as
CD4 and CD8 cells.
We recently developed a flexible and highly specific method to
restrict LV-mediated gene transfer to a cell type of choice and
demonstrated proof-of-principle by generating vectors specific for
hematopoietic stem cells, B lymphocytes, endothelial cells, and
neurons.10 The technology relies on engineered glycoproteins of
measles virus (MV), which are the hemagglutinin (H) and fusion
(F) proteins, both incorporated into the envelope membrane of
LV particles.10 Cell-type specificity is provided through a single-
chain antibody (scFv) that recognizes a cell-surface antigen
selectively expressed on the cell type of interest fused to an
engineered H protein, which is blinded for its natural receptors
CD46 (complement regulatory protein) and CD150 (signaling
lymphocyte activation molecule, SLAM). The extension of this
technology to other target cell types of interest relies on the
availability of suitable scFv. These must not only be specific for the
target cell but also have to be efficiently expressed on the surface of
the packaging cells as H protein fusion to become readily
incorporated into vector particles.11
In this study, we generated a CD8-specific scFv that allows
LV-mediated gene delivery using the CD8 surface molecule as
receptor for cell entry. This vector, CD8-LV, transferred genes
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exclusively into the CD8 subset of T cells, in vitro as well as in
vivo. Expression of melanoma-reactive TCRs exclusively in CD8
T cells significantly enhanced tumor-cell killing compared with
conventional gene transfer mediated by a nontargeted LV.
Methods
Plasmid constructions
The CD8-scFv coding sequences were amplified by reverse transcription of
OKT8 hybridoma mRNA followed by PCR using the heavy and light
primer mix (GE Healthcare) as previously described.10 The CD8-scFv CDR
coding regions were grafted into the HuCAL consensus frameworks huVH1
and huVL1,12 the resulting sequence was synthesized with optimized codons
(Geneart), and inserted into pCG-Hmut backbone via SfiI and NotI.10
Transfer vector plasmids encoding the TCRs T58 and D115, both
specific for the melanocyte antigen tyrosinase369-377 (YMDGTMSQV),
were constructed by excision of the transgene cassette from the -retroviral
vector MP71 and subcloning the coding sequences into the lentiviral vector
pRRL.PPT.MPpre. This vector is derived from pRRL.PPT.MP.GFPpre,
which is a third generation LV13 with an internal MPSV (myeloproliferative
sarcoma virus) U3 promoter, which is particularly active in lympho-
cytes.14,15 To construct pRRL.PPT.MP.GFPpre, the MPSV U3 was ampli-
fied via PCR using primers 5MPSV nhe (5-GAGCTAGCTTAAGTAAGC-
CATTTTGCAAGG-3; restriction sites underlined) and 3 MPSV bam age
(5-GACCGGTGGATCCCGGGCCCGCGGTACCCCGGGCGAC-3) on
retroviral vector template pMP71.16 The resulting NheI/AgeI fragment was
introduced into pRRL.PPT.SF.GFPpre17 to substitute for the internal
promoter of this vector. Sequence details are available on request. Because
the constant regions of both TCR chains were replaced by murine
counterparts, the transgenic TCR can be distinguished from endogenous
TCR by anti–mouse constant region of TCR -chain (mC) monoclonal
antibody (mAb) staining.18
Cell lines and primary cells
Cultivation of HEK293T cells has been described.19 The T-cell lines Molt
4.8, Jurkat 76 deficient of endogenous CD8 expression (J76), J76 stably
transduced with CD8 (J76CD8),20 and J76CD8 stably transduced with
SLAM (J76CD8SLAM), were grown in RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS) and 2mM L-glutamine (L-Glu).
J76CD8SLAM cells were generated by transduction of J76CD8 cells with
the retroviral vector MP71 encoding SLAM (CD150). Bulk culture was
stained with antibodies and revealed more than 85% of CD8 and SLAM
double-positive cells. The human melanoma cell lines, Mel-624.38 (HLA-
A2, Tyr),21 Mel-A375 (HLA-A2, Tyr, ATCC: CRL-1619), and
SK-Mel-28 (HLA-A2, Tyr, ATCC: HTB-72), were cultured as de-
scribed.9 Human PBMCs were isolated, cultivated, and activated as
described.22 Primary CD8 T cells were isolated by depletion of CD8 cells
using a CD8 T cell isolation kit (Miltenyi Biotec). Purified cells were
stimulated for 3 days in 24-well plates precoated with anti-CD3 (1 g/mL)
and anti-CD28 (1 g/mL) mAbs (BD Bioscience). Cells were then cultured
in RPMI 1640 medium supplemented with 10% FBS, 2mM L-Glu, 1mM
HEPES, 100 U/mL penicillin-streptomycin, and 100 IU/mL IL-2 (Roche).
Vector particle production and titration
Vector particles were generated as described10 using polyethylenimine (PEI)
for transfection of HEK293T cells. To produce CD8-LV, 1.5	 107 cells were
cotransfected with 1.9g of pCG-H-CD8opt, 9.3g of F protein expression
plasmids pCG-Fc
30,19 28.7g of HIV-1 packaging plasmid pCMV
R8.9, and
30.2g of the transfer vector plasmid pSEW encoding GFP, or the TCR-encoding
transfer vector plasmids pLV-T58 and pLV-D115, respectively. MV-LV and
VSV-G-LV were produced as described.19 After 2 days, vector particles released
into the cell supernatant were concentrated and purified by ultracentrifugation
through a 20% (wt/vol) sucrose cushion (120 000g for 3 hours at 4°C).
The supernatant was discarded and pellets were resuspended in 100L
OptiMEM or PBS.
To determine the titers of CD8-LV and VSV-G-LV stocks, Molt 4.8 cells
were transduced by at least 4 serial dilutions of vector particles. GFP cells
or transgenic TCR cells stained by anti-mCmAb were quantified by flow
cytometry. Titer calculation was based on those dilutions showing a linear
correlation with the dilution factor. Typical titers for CD8-LV ranged
between 5 	 106 and 2 	 107 transduction units (tu)/mL.
Transduction of cells and antibody competition assay
For transduction, 1 	 105 cells were incubated with vector particles and
4 g/mL protamine sulfate (Sigma-Aldrich) in a final volume of 300 L for
3 hours before 1 mL fresh medium was added. After 2 days, transgene
expression was determined by flow cytometry. For antibody competition
assay, different amounts of soluble OKT8 antibody or isotype matched
antibody were added to J76CD8SLAM cells before transduction. Two days
after transduction, the percentage of GFP cells was determined by flow
cytometry and the relative transduction efficiency was normalized to
transduction without antibody treatment. To study gene transfer in mixed
cultures of target and nontarget cells, J76 and J76CD8 cells were mixed at a
ratio of 1:1, and transduced by CD8-LV or VSV-G-LV at an MOI of 2.
To transduce activated PBMCs and purified CD8 T cells, cells were
incubated together with vectors and 4 g/mL protamine sulfate by centrifu-
gation for 1.5 hours at 800g, 32°C, 3 days after cell activation. Then cells
were cultured in the presence of 100 IU/mL IL-2. For killing assays and
intracellular staining, 12 days after transduction, PBMCs and CD8 T cells
were cultivated for 2 to 3 days in medium containing low amounts of IL-2
(10 IU/mL) to stop proliferation.
Flow cytometry
FACS analysis was performed using the LSRII flow cytometer, and data
were analyzed with FACS Diva software (both Becton Dickinson). A
phycoerythrin (PE)–conjugated anti-His mAb (Miltenyi Biotec) was used
to detect the expression of His-tagged H-CD8 protein. An allophycocya-
nin (APC) or PE-conjugated mAb to human CD8 (BD Pharmingen) was
used to detect CD8 cells. Surface expression of TCR-T58 or TCR-D115 in
transduced cells was detected by an APC-conjugated anti-mC mAb (BD
Pharmingen). For functional TCR-T58 or TCR-D115 detection, cells were
stained with a PE-labeled HLA-A*0201-Tyr multimer (Beckman Coulter).
To identify effector cell activation in the presence of target tumor cells,
anti–human CD69-PE mAb (BD Pharmingen) was added to the assay tubes
immediately after termination of the killing assay (E:T  2:1). Isotype
control stainings were performed in all experiments.
For intracellular staining to detect GrB and perforin in stimulated
effector cells, GrB and perforin specific mAbs were applied according to
the manufacturer’s instructions (Cytofix/Cytoperm kit with GolgiPlug; BD
Bioscience). Stimulations were performed for 4 hours at 37°C in a 96-well
plate containing 1 	 105 effector cells and 5 	 104 target cells in the
presence of 1 L/mL BD GolgiPlug. The cells were stained with anti-CD8
and anti-mC mAbs, washed, and permeabilized, followed by intracellular
staining with anti–human GrB-PE mAb, anti–human perforin-PE mAb, or
appropriate isotype controls (BD Pharmingen). Gated CD8/TCR-T58
cells were analyzed for presence of GrB and perforin.
Tumor cell killing assay
Cytotoxic activity of TCR-modified PBMCs or CD8 T cells was analyzed
in FACS-based assays as described.23 Briefly, 4 	 106/mL target tumor
cells were labeled with 1.5 L/mL calcein violet AM (Invitrogen) for
30 minutes on ice, washed 4 times with RPMI medium, resuspended in
T-cell culture medium, and counted. Subsequently, transduced T cells,
which were growth arrested by cultivation in 10 IU/mL IL-2–containing
medium for 2 to 3 days, were incubated with calcein violet AM-labeled
target tumor cells at different E:T ratios. To normalize the number of
effectors used and achieve the indicated E:T ratios, the number of
CD8/TCR cells added to targets was determined using the CD8 and
HLA-A2–Tyr antibodies previously described. Four hours after coincuba-
tion, 0.2 g propidium iodide (PI; Sigma-Aldrich) were added to stain for
dead cells, and the cells were immediately analyzed by flow cytometry.
Controls included calcein violet AM-stained target cells as well as PI and
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calcein violet AM–double-stained targets to determine spontaneous lysis.
Analysis was performed by gating on the calcein violet AM-labeled target
cells, and measuring the PI versus PI cells. Dead target cells were
determined as calcein violet AM and PI double-positive. The percentage of
specific tumor cell lysis was calculated by the following equation: (PI
calcein violet AM cells/total number of calcein violet AM cells) 	 100,
corrected for the number of spontaneously lysed targets.
In vivo analysis of CD8 targeting
Experimental mouse work was carried out in compliance with the
regulations of the German animal protection law. NOD-scid-IL2rnull mice
were bred and maintained under specific pathogen-free conditions and used
between 8 and 12 weeks of age. Freshly isolated human PBMCs were
stimulated as described for 3 days, and were intraperitoneally injected into
NOD-scid-IL2rnull mice. Seven days after PBMC transfer, mice were
intraperitoneally injected with CD8-LV-GFP, whereas mice in the control
group were intraperitoneally injected with PBS. Mice were killed 7 days
after vector particles injection and peritoneal washes were performed using
5 mL PBS. The peritoneal cells were stained by PE-conjugated anti–human
CD45 mAb (BD Pharmingen), and the percentage of GFP cells within
CD45 human cells was determined by flow cytometry.
Statistical analysis
Results are expressed as mean  SEM. Data were considered statistically
significant for P  .05. Differences in H-CD8 surface expression and in
CD69 activation marker expression were evaluated by 1-way ANOVA
followed by Tukey test. Percentages of tumor cell lysis mediated by
different vector-transduced effector cells in killing assays, and long-term
CD8 expression of effector cells were evaluated by 2-way ANOVA to
determine significant differences between pairs of groups. Differences in
GFP and TCR expression were evaluated by Student t test. Differences in
GrB and perforin expression were evaluated by paired t test. All statistical
calculations were done using Prism 5 software (GraphPad).
Results
Generation and characterization of CD8-LV
To generate a CD8-specific scFv, we cloned the coding sequences
of the variable domains of the heavy (VH) and light chain (VL) from
the antibody expressed by the murine hybridoma cell line OKT8.24
These were assembled to a scFv and then fused to the MV H
Figure 1. Characterization of CD8-LV. (A) Schematic representation of the H-CD8 expression construct and CD8-LV. The MV H protein is truncated at its cytoplasmic tail by
18 amino acids (CT
18). Four point mutations (Y418A, R533A, S548L, and F549S) in the ectodomain (ED) marked by asterisks abolish natural receptor recognition. The
displayed CD8-scFv is linked to H protein via a glycine-serine linker [(G4S)3]. The transmembrane domain (TM) and a histidine tag (6His) are indicated. (B) Expression plasmids
encoding H-CD8 and H-CD8opt were transfected into HEK293T cells. Two days later, surface expression of H-CD8 was quantified by anti-His mAb staining and FACS
analysis. The backbone plasmid pCG-1 was used as negative control. Results are expressed as mean  SEM (n  3; ***P  .001). (C) Transduction of J76CD8SLAM cells by
CD8-LV (black circles), VSV-G-LV (gray diamonds), and MV-LV (gray hexagons) was competed on preincubation of cells with the indicated concentration of OKT8 antibody for
20 minutes at 4°C. After 2 days, transduction efficiency was quantified. Isotype control antibody preincubated cells followed by CD8-LV transduction were included as further
control (black squares). (D) To study the specificity of CD8-LV, equal numbers of J76 cells and J76CD8 cells were mixed and transduced with the indicated vectors (MOI  1) or
left untransduced (ut). After 48 hours, the percentages of CD8/GFP and CD8/GFP cells were determined by flow cytometry. (E) Freshly isolated human PBMCs were
stimulated with 100 IU/mL IL-2 and anti-CD3/CD28 mAbs (1 g/mL) for 3 days and then transduced with CD8-LV or VSV-G-LV at an MOI of 2. Six days after transduction,
PBMCs were analyzed by flow cytometry for GFP expression and CD8 staining.
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reading frame resulting in plasmid pCG-H-CD8 encoding CD8-
scFv fused H protein (H-CD8; Figure 1A; supplemental Figure 1,
available on the Blood Web site; see the Supplemental Materials
link at the top of the online article). When pCG-H-CD8 was
expressed in HEK293T cells we observed only moderate cell
surface expression levels of H-CD8 protein, which were insuffi-
cient to release high-titer vector particles (Figure 1B). In an attempt
to enhance vector titers, we identified the 6 complementarity
determining regions (CDRs) and grafted them into the framework
of the most similar human variable domain sequences (supplemen-
tal Figure 1). This humanized CD8-specific scFv, CD8-scFvopt,
specifically bound CD8 but not CD8 cells (supplemental Figure
2). The corresponding H-CD8opt protein was efficiently expressed
on the cell surface (Figure 1B) and allowed the generation of
high-titer CD8-LV stocks.
To assess whether gene transfer mediated by CD8-LV was
because of the displayed CD8-specific scFv, we transduced CD8
cells in presence of OKT8. As shown in Figure 1C, OKT8
dramatically reduced CD8-LV–mediated transduction in a
concentration-dependent manner, whereas the addition of isotype
control antibody had no effect. Moreover, the presence of OKT8
did not influence transduction mediated by MV-LV,25 carrying
nonblinded MV glycoproteins, or VSV-G-LV. This result demon-
strates that transduction mediated by CD8-LV was because of the
displayed scFv. Next, we evaluated the specificity of CD8-LV in
mixed cultures of human CD8 and CD8 T-cell lines (Figure 1D)
or on human PBMCs (Figure 1E). Although VSV-G-LV transduced
both CD8 T cells and CD8 T cells with an overall similar
efficiency, CD8-LV only transduced the CD8 cells but left CD8
T cells untransduced. Of note, MV-LV transduced both CD8 and
CD4 cells in freshly isolated PBMCs with a preference for CD4
cells (Frecha et al26 and data not shown), which further proved that
the specificity of CD8-LV was caused by the displayed scFv and
not simply by the MV envelope. To assess the stability of gene
transfer and to exclude any toxic effects exerted by CD8-LV,
transduced cells were cultivated and the percentages of GFP cells
were followed more than time. The data demonstrate that the level
of GFP cells was stable during the observation period in cell lines
as well as PBMCs (supplemental Figure 3).
CD8 T cell specific gene transfer in vivo
The in vivo targeting potential of CD8-LV was studied in immuno-
deficient mice grafted with human PBMCs. Stimulated human
PBMCs were injected intraperitoneally into NOD-scid-IL2rnull
mice (Figure 2A). CD8-LV or PBS as control was intraperitoneally
injected 1 week after PBMC transplantation. After another week,
approximately two-thirds of the cells were CD8 in both PBS and
CD8-LV injected mice (Figure 2B). On average, approximately
10% of the cells were GFP although only a single dose of vector
particles had been applied. Remarkably, all GFP cells also stained
positive for human CD8 in each of the mice investigated (Figure
2C). Thus, CD8-LV targeted human CD8 cells in a humanized
mouse model specifically and efficiently.
Efficient delivery of therapeutic transgenes to CD8 cells
Next, we investigated whether tumor-reactive TCRs can be effi-
ciently delivered into CD8 T cells using CD8-LV. Because
VSV-G-LV is the most frequently used LV vector type, we
compared CD8-LV to this sort of gold standard vector. In all
upcoming experiments, the 2 vector types just differ in their
envelope glycoproteins, whereas vector core and transfer vector are
identical. Two tyrosinase (Tyr) peptide-specific, HLA-A2–
restricted TCRs, TCR-T58 and TCR-D115, were selected, which
differ 100-fold in their affinity.18 After transferring the TCR genes
into human PBMCs by CD8-LV or VSV-G-LV, TCR expression
was quantified by HLA-A2–Tyr multimer staining. CD8-LV–
transduced PBMCs expressed the TCR exclusively in the CD8
cell fraction, whereas on VSV-G-LV transduction, both, CD8 and
CD8 cells were TCR (Figure 3A-B). Of note, the majority (more
than 90%) of CD8 cells stained positive for CD4 (data not
shown), meaning VSV-G-LV transduced both CD8 and CD4
T cells, whereas CD8-LV left CD4 cells untransduced. To
compare the transduction efficiency of CD8-LV and VSV-G-LV on
Figure 2. In vivo targeting of CD8 cells. (A) Outline of the experimental setup. Human PBMCs were activated for 3 days after isolation, and 1 	 107 cells were
intraperitoneally injected into NOD-scid-IL2rnull mice. One week later, CD8-LV particles (8 	 105 transduction units per mouse), or PBS as a control, were intraperitoneally
injected. Peritoneal cells were collected 1 week after vector injection and analyzed by flow cytometry. (B) Representative FACS data demonstrating specific transduction of
human CD8 T cells in the peritoneal cavity. Isolated peritoneal cells from PBS or CD8-LV–injected mice were stained with anti–human CD8 mAb, and the percentage of
human CD8/GFP cells was analyzed. (C) Percentages of GFP cells in hCD8 T cells (gray bars) and hCD8 T cells (white bars) were calculated according to panel B.
Results are expressed as mean  SEM (n  4; *P  .05; nd indicates not detectable).
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monocultures of CD8 cells, we purified CD8 T cells by negative
selection and transduced the cells with both vector types at the
same MOI as determined on Molt cells. As shown in Figure 3C-D,
both TCR-T58 and TCR-D115 expression was superior using
CD8-LV compared with VSV-G-LV–mediated gene transfer. These
data demonstrate that CD8-LV specifically delivered more complex
genes, such as TCR  and -chains into CD8 T cells and was
more efficient than VSV-G-LV.
Efficient tumor cell killing by CD8-LV TCR gene-modified T cells
Next, we investigated the cytotoxic potential of CD8-LV and
VSV-G-LV–transduced T cells expressing tumor cell-reactive TCRs. To
adjust for the more efficient TCR gene delivery mediated by CD8-LV,
we added relatively more VSV-G-LV–transduced cells to reach equiva-
lent effector to target (E:T) ratios in the tumor cell killing assay for both
types of vector-transduced cells. Both, T58 and D115 TCR-transduced
cells specifically recognized and killed Tyr/HLA-A2 tumor cells, but
not Tyr or HLA-A2 control tumor cells. Remarkably, CD8-LV–
transduced cells reproducibly killed tumor cells more efficiently than
VSV-G-LV–transduced cells (Figure 4A, supplemental Figure 4). To
achieve a similar level of tumor cell killing as that mediated by CD8-LV
TCR-transduced T cells, between 5 and 10 times more VSV-G-LV
TCR-transduced effector cells had to be applied (Figure 4A; compare
1:1 and 5:1 ratios of the CD8-LV-T58 samples with 5:1 and 20:1 of
VSV-G-LV-T58 samples, respectively).
Although in the assay described in the previous paragraph the
numbers of TCR T cells were equal for both vector types,
significantly more noneffector cells were present in the cell
mixtures for the VSV-G-LV than for the CD8-LV samples. Thus,
redundant noneffectors might have potentially obstructed the
effector T cells to recognize and kill tumor cells during the 4-hour
incubation period of the killing assay. To exclude that the observed
enhanced killing mediated by CD8-LV–transduced cells was
simply because of the experimental setup, we transduced PBMCs
with VSV-G-LV at an MOI of 100, thereby reaching 35.8% of
CD8/TCR-T58 cells, a percentage almost identical to that
obtained with CD8-LV at an MOI of 2 (36.3%). In addition,
PBMCs were transduced with VSV-G-LV at an MOI of 2 (16.8% of
CD8/TCR-T58 cells), and the number of effector cells and E:T
ratios were normalized as before. As shown in Figure 4B, there was
no difference in the killing efficiency between VSV-G-LV TCR-
transduced cells at MOI of 2 and 100. Thus, redundant noneffector cells
did not influence the killing efficiency in our experimental setup.
CD8-LVTCR-transduced cells again displayed a substantially enhanced
killing activity, which must be because of specific properties of the
CD8-LV vector rather than its enhanced CD8 cell transduction
efficiency.
It is widely accepted that CD4 helper T cells augment CD8
T-cell–mediated tumor control and eradication, although in a
short-term killing assay this helper function may be limited.27-29 To
exclude any effect mediated by CD4 T cells, we purified CD8
T cells from PBMCs, transduced them with both vector types and
performed the killing assay. Similarly as with PBMCs, TCR-T58–
modified CD8 T cells killed tumor cells more efficiently when the
Figure 3. Efficient TCR gene delivery by CD8-LV.
Activated human PBMCs were left untransduced (ut) or
transduced by CD8-LV or VSV-G-LV harboring either the
TCR-T58 (A), or the TCR-D115 transgene (B) at an MOI
of 2. Transduced PBMCs were analyzed after 7 days for
TCR expression using HLA-A2-Tyr multimer staining.
Percentages of CD8/multimer cells are displayed in
the upper right gate. (C-D) Purified human CD8 T cells
were activated for 3 days and transduced by CD8-LV or
VSV-G-LV at an MOI of 2. Seven days later, percentages
of TCR-T58 (C) or TCR-D115 cells (D) were deter-
mined by flow cytometry. Results are expressed as
mean  SEM (n  3; *P  .05; ***P  .001).
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cells had been transduced with CD8-LV (Figure 4C). This result
was confirmed with the low affinity tyrosinase-reactive TCR-D115.
Also in this case, CD8-LV–transduced CD8 T cells were superior
in cell killing compared with VSV-G-LV–transduced T cells
(supplemental Figure 4). Furthermore, the enhanced killing activity
of CD8-LV TCR-transduced T cells correlated positively with the
levels of granzyme B (GrB) and perforin expression. As summa-
rized in Figure 5, VSV-G-LV–transduced cells expressed lower
amounts of GrB and perforin than CD8-LV–transduced cells.
Increased CD8 coreceptor expression levels in
CD8-LV–transduced cells
To further investigate the molecular mechanism causing the
enhanced antitumoral response of CD8-LV–transduced cells, trans-
genic TCR and surface CD8 expression levels were determined
before performing the killing assay. Because the same number of
effector cells transduced by CD8-LV and VSV-G-LV was used,
differences in the amounts of transgenic TCR per cell might have
affected effector cell activation and target cell lysis. Therefore, we
quantified the TCR-T58 surface density on effector cells. As shown
in Figure 6A, no difference was observed in surface TCR-T58
levels between CD8-LV and VSV-G-LV–transduced effector cells.
Thus, differences in transgenic TCR densities can be ruled out as
causative for the enhanced cytotoxic activity mediated by CD8-LV.
Previous studies have shown that CD8 is important for CD8
T-cell signaling,30 and changes in CD8 levels can affect T-cell
function.31 Thus, we next quantified the CD8 surface density in
Figure 4. Efficient tumor cell lysis by CD8-LV TCR-transduced T cells. Activated PBMCs (A-B) or purified CD8 T cells (C) were transduced with CD8-LV or VSV-G-LV at
the indicated MOIs, and expanded in 100 IU/mL IL-2–containing medium. On day 12, transduced cells were transferred into 10 IU/mL IL-2–containing medium for 2 to 3 days,
and TCR-T58 expression was determined by HLA-A2-Tyr multimer staining (data not shown). Identical numbers of CD8/TCR-T58 cells were applied as effector cells and
used to normalize E:T ratios. (A) TCR-T58-modified PBMCs were incubated with Mel-624.38 cells or as controls with Mel-A375 or SK-Mel-28 cells at the indicated E:T ratios for
4 hours, and target cell killing was quantified using a FACS-based cytotoxicity assay. Mean values  SEM calculated from 3 independent experiments are shown. The
difference between CD8-LV-TCR-T58 and VSV-G-LV-TCR-T58 (MOI  2) treated groups is highly significant (P  .0001). (B) TCR-T58–expressing PBMCs transduced by the
indicated vectors at the indicated MOIs were incubated with Mel-624.38 cells for 4 hours. Mean values  SEM calculated from 2 independent experiments are shown. The
difference between CD8-LV-TCR-T58 and VSV-G-LV-TCR-T58 (MOI  100) treated groups is significant (P  .0001), whereas the difference between VSV-G-LV-TCR-T58
(MOI  2) and VSV-G-LV-TCR-T58 (MOI  100) treated group is not (P  .05). (C) Purified CD8 T cells transduced by the indicated vectors were incubated with Mel-624.38
cells for 4 hours, and specific target-cell lysis was determined. Representative results from 1 of 2 independent experiments with T cells from 2 different donors are shown. The
difference between CD8-LV-TCR-T58 and VSV-G-LV-TCR-T58 (MOI  2) treated groups is significant (P  .001).
Figure 5. Granzyme B and perforin in CD8-LV TCR-
transduced T cells. PBMCs were treated as described
in Figure 4. CD8-LV-TCR-T58 or VSV-G-LV-TCR-T58–
transduced PBMCs (MOI  2) were incubated with Mel-
624.38 (E:T  2:1) in the presence of GolgiPlug. After
4 hours, cells were surface stained with anti-CD8 and
anti-mC mAbs to determine the total number of effector
cells (CD8/TCR-T58), and intracellularly stained with
specific mAbs to determine the percentage of GrB (A) or
perforin (B) expressing cells. Data are from 5 different
donors. Individual symbols represent individual donors to
visualize trends per donor. Bars represent median values
(*P  .05; **P  .01).
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CD8/TCR-T58high effector cells (supplemental Figure 5), where a
sufficient number of transgenic TCRs were expressed to exceed the
activation threshold required for cytokine release and cytotoxic
activity. As shown in Figure 6B, the CD8 density was slightly but
significantly enhanced in cells transduced by CD8-LV compared
with VSV-G-LV–transduced cells. This observation was consis-
tently made at several time points over a 12-day cultivation period
with the only exception shortly after transduction (Figure 6B).
Furthermore, we quantified expression of the T-cell early
activation marker CD69 after cocultivating effector and target
cells. In absence of target cells, untransduced T cells as well as
CD8-LV and VSV-G-LV–transduced T cells expressed only low
levels of CD69 (Figure 6C-D). After adding target cells, both types
of vector transduced cells displayed significantly higher levels of
CD69 than untransduced T cells. Importantly, CD8-LV–transduced
cells thereby expressed higher amounts of CD69 than VSV-G-LV–
transduced cells. There were significantly more CD69 cells, and
also the CD69 density was increased (Figure 6C-D). These data
suggest that the enhanced antitumoral activity of CD8-LV–
transduced cells was because of an enhanced activation and
increased CD8 expression levels.
Discussion
We present here the first gene vector (CD8-LV) that delivers genes
precisely and exclusively to CD8 T cells. The vector is derived
from lentiviral vectors, which exhibit several unique advantages,
such as the ability to transduce minimally stimulated32,33 or
nonstimulated T cells,22,26 as well as a preference for safer
integration sites compared with -retroviral vectors.34 LVs have
therefore recently been suggested as attractive alternative to
-retroviral vectors, which are at present commonly used for TCR
gene transfer.1-3 The selectivity of CD8-LV for CD8 cells relies on
the high specificity of antibody-antigen recognition. As targeting
domain, a scFv antibody fragment was generated from the broadly
used mAb OKT8, which is specific for the -chain of CD8.
Notably, the scFv as such was not suited as targeting domain. Only
by grafting its CDR regions into a human scFv framework we were
able to convert the OKT8-derived scFv into a fully functional
targeting domain. It is conceivable that this engineering step
improved folding and enhanced stability of the scFv thereby
increasing expression levels and cell-surface transport of the
H-scFv fusion protein.11
CD8-LV discriminated between CD8 and CD8 cells with
virtually absolute specificity, although retaining high transduction
efficiency and stable gene delivery. Remarkably, this was not only
the case ex vivo on primary cells, but also in vivo where CD8-LV
selectively transferred genes into CD8 T cells in NOD-scid-
IL2rnull mice transplanted with human PBMCs. This suggests that
CD8-LV will be applicable for in vivo gene transfer strategies.
CD8-LV maintained its specificity and efficiency even when
delivering more complex genes, such as TCR encoding sequences.
Thus, CD8-LV is the first transfer vector that delivers genes
exclusively to CD8 cells. In principle, target cells of CD8-LV
include all CD8 cells, which are besides CD8 T cells dendritic
cells and natural killer cells.35 Although these cells may form an
attractive target for antigen delivery, they will neither survive the
ex vivo expansion nor express introduced TCR genes and therefore
are not relevant for TCR gene therapy.
Although titers of CD8-LV stocks were on average approxi-
mately 100-fold lower than those of VSV-G-LV, CD8-LV was more
efficient than VSV-G-LV in delivering TCR genes to CD8 T cells.
An unexpected and remarkable outcome of this study was the
substantially enhanced tumor-cell killing activity of CD8-LV
versus VSV-G-LV TCR–transduced effector T cells. To achieve a
Figure 6. Increased CD8 density and enhanced activation of CD8-LV TCR-transduced cells. (A) Activated PBMCs were transduced with CD8-LV-TCR-T58 or
VSV-G-LV-TCR-T58 at an MOI of 2. Approximately 2 weeks later, TCR expression levels were determined using HLA-A2-Tyr multimers in the presence of anti-CD8 mAb. Mean
fluorescent intensities (MFI) of the TCR specific signal are shown for the transduced effector cells of each vector type. Results are expressed as mean  SEM (n  10). ns
indicates not significant. (B) Activated PBMCs were transduced with CD8-LV-TCR-T58 (dark gray line) or VSV-G-LV-TCR-T58 (light gray line) at an MOI of 2. Then,
CD8/TCR-T58high cells were gated (supplemental Figure 5), and CD8 surface densities were determined at the indicated days as relative MFI normalized to that of
untransduced cells. Results are expressed as mean  SEM (n  3). The difference between CD8-LV-TCR-T58 and VSV-G-LV-TCR-T58 treated groups is significant
(P  .05). (C-D) Activated PBMCs were left untransduced (white bars), transduced by VSV-G-LV-TCR-T58 (gray bars), or CD8-LV-TCR-T58 (black bars). Cells were then
cultivated for 12 days, before they were transferred into IL-2 (10 IU/mL) containing medium for 3 days. Effector cells were incubated with or without Mel-624.38 cells for 4 hours
and stained with anti-CD8, anti-mC, and anti-CD69 mAbs or appropriate isotype controls. The gate determining CD69 cells was set according to the isotype control antibody
stained untransduced cells. Overall percentage of CD69 cells (C), and MFI of CD69 cells (D) among CD8/TCR-T58high cells are shown. Results are expressed as
mean  SEM (n  3; *P  .05; ***P  .001).
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similar efficiency in target cell lysis, approximately 5 to 10 times
more effector cells transduced with VSV-G-LV were required. This
difference became even more pronounced when a pure culture of
CD8 T cells was transduced, and, although to a lower extend, was
also observed when the low affinity TCR-D115 was applied.
Straightforward explanations such as differences in the amounts of
introduced TCR expressed on the cell surface or the sensitivity of
modified T cells toward activation-induced cell death on tumor
antigen restimulation (supplemental Figure 6) were excluded as
being responsible for the different tumor killing activity of CD8-LV
versus VSV-G-LV–transduced cells. These data demonstrate that this
effect was not limited to a particular type of TCR, and was not because
of the CD8 cell targeting capability of CD8-LV. Rather, it must have
been a consequence of CD8-LV particle binding to CD8 followed by
membrane fusion and cell entry.
Human CD8 is a heterodimeric protein that binds to MHC class
I molecules.36 Although its binding affinity to pMHC is weaker
than that of TCRs, it is well established that the interaction between
CD8 and MHCI is critical for T-cell activation and lysis of target
cells.37-40 Several previous studies have confirmed that higher
CD8 levels (1) positively correlate with the sensitivity of TCRs for
antigens and the cytolytic activity of T cells,41,42 (2) enhance the
avidity of TCRs for the p-MHCI complex,43 and (3) enhance the
expression of perforin and granzymes resulting in increased
cytotoxicity.44 We observed in CD8-LV but not in VSV-G-LV
TCR-transduced T cells a small subpopulation of cells exhibiting a
slight but significant up-regulation of CD8 surface expression. One
likely explanation is that CD8-LV preferentially transduced T cells
with the highest CD8 density. We previously found that gene
transfer efficiency positively correlated with target receptor density
for CD105-LV10 and Her2neu-LV.11 Alternatively, binding of
CD8-LV to CD8, similarly as antibody-antigen binding, may have
led initially to CD8 down-regulation and then to an over-
compensated up-regulation of CD8 expression. In fact, CD8 levels
transiently declined 2 days after CD8-LV transduction, but then
steadily increased.
A recent study investigating systematically the influence of a
panel of CD8-specific mAbs on CD8 T cell effector functions
revealed a unique property for OKT8: of 8 antibodies tested only
OKT8 induced effector functions of CD8 cells.30 Although a
monovalent Fab fragment of OKT8 failed to activate CD8 T cells,
the corresponding bivalent F(ab)2 fragment retained some ability
to enhance pMHCI tetramer staining.30 This suggests that for
activation the Fc part of the antibody itself is not essential, whereas
multiple CD8 contacts are indeed important. Lentiviral vectors
produced in packaging cells can contain approximately 100 envelope
proteins per particle.45 We found around 80 MV H proteins per particle
by quantitative mass spectrometry (N. Kirsch and C.J.B., unpublished
data, December 20, 2010). It is thus probable that multiple scFv/CD8
contacts are formed during entry of a single CD8-LV particle into a
single CD8 effector cell.
Moreover, we found increased GrB and perforin levels in
CD8-LV TCR-transduced T cells compared with VSV-G-LV–
transduced cells, although both cell types showed equivalent IFN-
and TNF- levels (supplemental Figure 7). Although these results
contrast with previous reports indicating a direct correlation
between IFN- release and cytotoxic activity of CTL clones and
TCR gene-modified T cells,46-48 they are in line with recent findings
that acute killing is characterized by GrB/perforin-induced cytotox-
icity, and that cytotoxicity may not necessarily correlate with
cytokine release, especially IFN- production.49 Also OKT8-
induced effector functions occur in absence of cytokine release.30
Taken together, it is probable that at least 2 mechanisms
contribute to the enhanced tumor cell killing induced by CD8-LV:
(1) activation of effector functions by binding of the displayed
OKT8-derived scFv molecules to CD8 on the surface of CD8
T cells via multiple contacts; and (2) up-regulation of CD8 surface
expression in a small subpopulation of TCR cells. Accordingly,
CD8-LV–transduced T cells would better stabilize the TCR/p-
MHC complex and reduce the TCR-dependent activation thresh-
old, leading to a stronger T-cell activation, more GrB and perforin
production, and more efficient tumor cell lysis compared with
T cells transduced by the conventional lentiviral vector. To further
test this hypothesis, the stabilization of the TCR/p-MHC complex
between CD8-LV and VSG-LV–transduced cells can be directly
compared by tetramer decay assay.
In summary, our study describes the first CD8 cell targeted
gene vector and demonstrates its successful application for in vivo
targeting and TCR gene therapy. The finding, that CD8 targeting
enhances the antitumoral activity of TCR-modified T cells, under-
scores the importance of the CD8 coreceptor function in T-cell
activation. A positive safety profile provided, this finding also
suggests that CD8-LV has the potential to improve the efficacy of
TCR gene therapy for cancer. Beyond that, exclusive gene transfer
to CD8 cells opens up novel options for therapeutic strategies of
other diseases such as chronic virus infections for which natural
TCRs or CARs can be used. Moreover, by local injection of
CD8-LV at sites of inflammation it may be possible to deliver, for
example suicide genes to selectively eliminate CD8 cells.
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